The Valley Desk

NCT04915755 · Interventional trial

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Overall registry status Active not recruiting

Phase 3

Conditions Neoplasms, Breast

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov